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A B S T R A C T
GABAB receptors assemble from GABAB1 and GABAB2 subunits. GABAB2 additionally associates with
auxiliary KCTD subunits (named after their K+ channel tetramerization-domain). GABAB receptors
couple to heterotrimeric G-proteins and activate inwardly-rectifying K+ channels through the bg
subunits released from the G-protein. Receptor-activated K+ currents desensitize in the sustained
presence of agonist to avoid excessive effects on neuronal activity. Desensitization of K+ currents
integrates distinct mechanistic underpinnings. GABAB receptor activity reduces protein kinase-A
activity, which reduces phosphorylation of serine-892 in GABAB2 and promotes receptor degradation.
This form of desensitization operates on the time scale of several minutes to hours. A faster form of
desensitization is induced by the auxiliary subunit KCTD12, which interferes with channel activation by
binding to the G-protein bg subunits. Here we show that the two mechanisms of desensitization
inﬂuence each other. Serine-892 phosphorylation in heterologous cells rearranges KCTD12 at the
receptor and slows KCTD12-induced desensitization. Likewise, protein kinase-A activation in
hippocampal neurons slows fast desensitization of GABAB receptor-activated K
+ currents while protein
kinase-A inhibition accelerates fast desensitization. Protein kinase-A fails to regulate fast desensitization
in KCTD12 knock-out mice or knock-in mice with a serine-892 to alanine mutation, thus demonstrating
that serine-892 phosphorylation regulates KCTD12-induced desensitization in vivo. Fast current
desensitization is accelerated in hippocampal neurons carrying the serine-892 to alanine mutation,
showing that tonic serine-892 phosphorylation normally limits KCTD12-induced desensitization. Tonic
serine-892 phosphorylation is in turn promoted by assembly of receptors with KCTD12. This cross-
regulation of serine-892 phosphorylation and KCTD12 activity sharpens the response during repeated
receptor activation.
 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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GABAB receptors are the G-protein coupled receptors (GPCRs)
for GABA, the main inhibitory neurotransmitter in the central
nervous system [1]. GABAB receptors are obligate heteromers
composed of GABAB1 (GB1) and GABAB2 (GB2) subunits. Two GB1
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0006-2952/ 2014 The Authors. Published by Elsevier Inc. This is an open access article undendritic distribution of the receptors [2]. In the heteromer GB1
binds GABA while GB2 facilitates surface trafﬁcking and binds the
G-protein [3–6]. GABAB receptors are expressed by most neurons
in the brain and regulate neuronal excitability by modulating the
activity of G protein-gated inwardly rectifying K+ channels (GIRK
or Kir3 channels), voltage-gated Ca2+ channels and adenylyl
cyclase [1,7,8]. To avoid prolonged effects on neuronal activity
in the continuous presence of GABA, GABAB receptors exhibit a
time-dependent decrease in receptor response, a phenomenon
referred to as homologous desensitization [9–12]. GABAB receptor
activity induces homologous desensitization through the inhibi-
tion of adenylate cyclase, which in turn decreases the cAMP-
dependent activity of protein kinase-A (PKA). Since PKA phos-
phorylation of serine-892 (S892) in the C-terminal domain of GB2
increases receptor stability at the plasma membrane, reduced PKAder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Fig. 1. S892 phosphorylation slows KCTD12-induced desensitization of baclofen-activated K+ currents. (A) Scheme highlighting the close proximity of the PKA
phosphorylation-site S892 and the KCTD12 binding-site Y902 in the C-terminal domain of GB2. (B) Representative traces of GIRK currents activated by baclofen (100 mM) and
recorded at 50 mV from CHO-K1 cells expressing GB2-WT, GB1b, GIRK1/2 and KCTD12. Cells were pre-incubated without (Control, black trace) or with 8-Br-cAMP (1 mM,
30 min; grey trace). The desensitization time constants t1 and t2 were derived from double-exponential ﬁts (blue trace) to the decay phase of K
+ currents during baclofen
application. (C) Representative traces as in (B) from CHO-K1 cells lacking KCTD12. (D–F) Representative traces as in (B) from CHO-K1 cells expressing the GB2 mutants S892A
(D), S892E (E) or Y902A (F). (G) Bar graph summarizing the time constant t (amplitude-weighted mean time constant calculated from t1 and t2) of baclofen-induced K
+
current desensitization. Data are means  SD, n = 5–16. *, p < 0.05; **, p < 0.01; ***, p < 0.001; Sidak’s multiple comparison test. (H) Repeated activation of GIRK currents in CHO-K1
cells expressing WT GABAB receptors (GB1,2-WT) together with KCTD12 results in a sharpening of the current response (left; 1st response black, 3rd response red). No sharpening of
the current response upon repeated activation is observed with mutated GABAB receptors (GB1,2-S892A) that cannot be phosphorylated at S892 (right). Baclofen applications were
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Fig. 2. S892 phosphorylation rearranges the receptor/KCTD12 complex. (A) Scheme of the BRET Rluc-KCTD12 donor and GB1a-YFP acceptor pair. (B) BRET donor saturation
curves from HEK293T cells expressing ﬁxed amounts of GB2-WT, GB2-Y902A (both left) or GB2-S892A (right) together with Rluc-KCTD12 and increasing amounts of GB1a-
YFP. Cells were pre-incubated with 8-Br-cAMP (1 mM, 30 min; open circles) to activate PKA. BRET is expressed as milli BRET units (mBU) determined as net BRET  1000. Data
points are means  SD of technical quadruplicates of a representative experiment, n = 4–7. (C) Western blot of lysates of HEK293T cells expressing GB1a-YFP, GB2-WT and Rluc-
KCTD12 in the presence and absence of 8-Br-cAMP (1 mM, 30 min pre-incubation). Activation of PKA does not affect the total amount of GB2 but increases phosphorylation at S892
(GB2-pS892). GB2 runs as two bands on SDS–PAGE, likely due to differences in posttranslational modiﬁcation. The higher molecular weight band appears to be more heavily
phosphorylated at S892. Blots are representative of six independent experiments. Bar graph summarizing the amount of S892 phosphorylation normalized to the amount of GB2 on
the same blot (GB2-pS892 in %). Data are means  SD, n = 6. *, p < 0.05; t test. (D) Co-immunoprecipitation of GABAB receptors with KCTD12 from HEK293T cells expressing GB1a-
YFP, GB2-WT and Rluc-KCTD12 in the presence and absence of 8-Br-cAMP (1 mM, 30 min pre-incubation). Equivalent amounts of GABAB receptors were co-precipitated. Blots are
representative of ﬁve independent experiments. (E) Co-immunoprecipitation of GABAB receptors with KCTD12 from HEK293T cells expressing GB1a-YFP, GB2 (WT, S892A, S892E or
Y902A) and Rluc-KCTD12. Y902A does not bind KCTD12 and was used as a negative control. Blots are representative of three independent experiments.
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sitization of the receptor response [13,14]. This phosphorylation-
dependent mechanism regulates desensitization on the time scale
of several minutes to hours. In addition, faster mechanisms induce
homologous desensitization of the receptor response within
seconds of agonist application. These mechanisms operate at the
G-protein rather than at the receptor. The ‘‘Regulator of G-protein
Signaling’’ (RGS) protein 4 induces desensitization by accelerating
the rate of GTP hydrolysis at the Ga subunit of the activated G-
protein [15–17]. Fast desensitization is additionally induced by the
KCTD proteins 12 and 12b [18,19]. The KCTDs are auxiliaryfor 60-s in intervals of 5 min. (I) Bar graph summarizing experiments as shown in (H). In 
compared to the t of the 1st response (tP1). No change in the desensitization of the curren
(S892A), (ii) with the phospho-mimetic S892E and (iii) when KCTD12 cannot bind to GB2receptor subunits that constitutively associate with the C-terminal
domain of GB2, in which mutation of Y902 to alanine (Y902A)
completely abolishes association [18,20,21]. KCTD12 induces
GABAB receptor-activated K
+ current desensitization by binding
to the bg subunits of the activated G-protein, which interferes
with activation of the effector K+ channel [19]. Of note, this post-
receptor mechanism of desensitization is rendered receptor-
speciﬁc through the exclusive association of native KCTD12
protein with GABAB receptors [19].
Since KCTD12 binds to GB2 in proximity of the PKA
phosphorylation-site S892 (Fig. 1A), phosphorylation of S892experiments with GB2-WT, the t of the 3rd response (tP3) was signiﬁcantly reduced
t response upon repeated activation is seen (i) when S892 cannot be phosphorylated
 (Y902A). Data are means  SD, n = 7–12. **, p < 0.01; t test.
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and vice versa, KCTD12 may inﬂuence S892 phosphorylation. We
therefore addressed whether PKA regulates KCTD12-induced K+
current desensitization. We found that PKA phosphorylation of
S892 reduces KCTD12-induced K+ current desensitization in
heterologous cells and cultured hippocampal neurons. Mechanis-
tically, S892 phosphorylation induces a conformational change in
the GABAB receptor/KCTD12 complex that slows KCTD12-induced
desensitization. Reciprocally, the binding of KCTD12 promotes
phosphorylation of S892, consistent with previous data showing
that KCTD12 stabilizes receptors at the cell surface [21].
2. Material and methods
2.1. Cell lines and cultures of hippocampal neurons
HEK293T and CHO-K1 cells were maintained in DMEM (Life
Technologies, CA, US) supplemented with 10% FBS (GE Healthcare,
Buckinghamshire, UK) at 37 8C with 5% CO2. CHO-K1 cells stably
expressing GB1 and GB2 subunits were cultured as described [22].
Cultured hippocampal neurons were prepared from wild-type
(WT), KCTD12/ [19,23] or GB2-S892A mice on embryonic day
16.5 as described [24].
2.2. Drugs
To activate GABAB receptors, baclofen (Cat.No. 417) was used at
a ﬁnal concentration of 100 mM. To activate PKA, 8-Br-cAMP
(Cat.No. 1140) and forskolin (Cat.No. 1099) were used at a ﬁnal
concentration of 1 mM and 20 mM, respectively. To inhibit PKA,
H89 (Cat.No. 2910) and protein kinase inhibitor-(14-22)-amide
(PKI, Cat.No. 2546) were used at a ﬁnal concentration of 2 mM or
10 mM, and 10 mM, respectively. All reagents were purchased from
Tocris Bioscience, UK.
2.3. Generation of GB2-S892A knock-in mice
The gene targeting construct contained a neomycin resistance
cassette (pRay-2; Genbank accession number U63120) ﬂanked by
two arms of Balb/c GB2 genomic DNA. The S892A mutation in exon
19 was introduced into the 30 arm along with a diagnostic silent
NheI restriction site. The targeting construct was electroporated
into Balb/c embryonic stem cells. Neomycin resistant colonies
were screened for homologous recombination by PCR, and positive
clones conﬁrmed by Southern blot. Positive ES cells were
microinjected into C57BL/6 blastocysts. Chimeric males were
crossed with female Balb/c mice to generate inbred Balb/c mice
heterozygous for the S892A allele. The neomycin cassette in the
S892A allele was then excised by mating heterozygous mice with
Balb/c Cre-deleter mice [25]. Whole brain membranes were probed
with the primary antibodies guinea-pig anti-GB2 (AB5394, 1:2000,
Millipore, Darmstadt, Germany), rabbit anti-GB2-pS892 [13]
(1:2000), rabbit anti-GB1 [26] (1:3000), mouse anti-b-III-tubulin
(T8660, 1:1000, Sigma–Aldrich, MO, US). All animal experiments
were subjected to institutional review and approved by the
Veterinary Ofﬁce of Basel-Stadt.
2.4. Molecular biology
The plasmids encoding HA-GB2, HA-GB2-Y902A, Myc-GB1b,
Flag-GB1a, pRK6-GB1a-YFP, pcDNA3.1-GIRK1/2, Myc-KCTD12,
pIRES-EGFP-KCTD12, Rluc-KCTD12 and Rluc-Gb1 were described
earlier [19,21,27,28]. The HA-GB2-S892A and HA-GB2-S892E
mutations were generated by replacing S892 with alanine or
glutamate, respectively. Lipofectamine 2000 (Life Technologies,
CA, US) was used for transient transfections. For electrophysiologywe co-expressed green ﬂuorescent protein (GFP) or pIRES-EGFP-
KCTD12. The amount of DNA in the transfections was kept constant
by supplementing with pCI plasmid DNA (Promega, WI, US).
2.5. Electrophysiology
CHO-K1 cells and cultured hippocampal neurons were plated
onto ThermanoxTM plastic coverslips (Thermo Scientiﬁc, MA, US) or
poly-L-lysine (P9155, Sigma–Aldrich, MO, US) coated glass cover-
slips, respectively. Experiments with CHO-K1 cells and cultured
hippocampal neurons were performed at room temperature 2–3
days or 1–2 weeks (DIV14-21) after transfection, respectively. Cells
were continuously superfused with an extracellular solution (ECS)
composed of (in mM): 145 NaCl, 2.5 KCl, 1 MgCl2, 2 CaCl2, 10 HEPES,
25 glucose; pH 7.3, 323 mosm. Neurons were superfused with ECS
supplemented with (in mM): 10 DNQX, 0.5 TTX, 100 picrotoxin, 5 D-
CPP. Patch pipettes had resistances between 3 and 4 MV when ﬁlled
with intracellular solution (ICS) composed of (in mM): 107.5
potassium gluconate, 32.5 KCl, 10 HEPES, 5 EGTA, 4 MgATP, 0.6
NaGTP, 10 Tris-phosphocreatine; pH 7.2, 295 mosm. To activate PKA
the ICS was supplemented with 250 mM 8-Br-cAMP. Series
resistance (<5 MV) was compensated by 80%. GABAB responses
were evoked by fast application of baclofen and recorded with an
Axopatch 200B patch-clamp ampliﬁer; ﬁltering and sampling
frequencies were set to 1 kHz and 5 kHz, respectively [29].
Desensitization time constants were derived from bi-exponential
ﬁts to the decay phase of GIRK currents during agonist application.
Curve ﬁtting and data analysis were done with pClamp10 software
(Molecular Devices, CA, US). Data are given as mean  SD.
Pharmacological treatments were carried out after DIV15 (neurons)
or 48 h after transfection (CHO-K1 cells). Before recording, hippocam-
pal neurons or CHO-K1 cells were pre-incubated for 30 min with 8-Br-
cAMP, forskolin, PKI and H89 in the ECS.
2.6. Co-immunoprecipitation experiments and drug treatments
Forty-eight hours after transfection, HEK293T cells were
starved for 4 h in DMEM w/o FCS prior to incubation for 30 min
with 8-Br-cAMP. Cells were harvested, washed once with ice-cold
PBS, and subsequently lysed in NETN buffer (100 mM NaCl, 1 mM
EDTA, 0.5% Nonidet P-40, 20 mM Tris/HCl, pH 7.4) supplemented
with complete EDTA-free protease inhibitor mixture (Hoffmann-La
Roche, Basel, Switzerland) and phosphatase inhibitors 2 and 3
(P5726 and P0044, Sigma–Aldrich, MO, US). After rotation for
10 min at 4 8C, the lysates were cleared by centrifugation at
1000  g for 10 min at 4 8C. Lysates were directly used for Western
blot analysis or immunoprecipitated with anti-Rluc antibody
(MAB4410, Millipore, Darmstadt, Germany) coupled to Dyna-
beads1 Protein-G (10004D, Life Technologies, CA, US). Lysates and
immunoprecipitates were resolved using standard SDS–PAGE and
probed with the primary antibodies guinea-pig anti-GB2 (AB5394,
1:2000, Millipore, Darmstadt, Germany) or guinea-pig anti-
KCTD12 [23] (1:1000) and peroxidase-coupled secondary anti-
bodies donkey anti-guinea pig (A7289, 1:10,000, Sigma–Aldrich,
MO, US). The chemiluminescence detection kit (Thermo Scientiﬁc,
MA, US) was used for visualization. The band intensity on Western
blots was quantiﬁed from non-saturated images using a Fusion FX
Chemiluminescence System (Vilber Lourmat, Witec AG, Lucerne,
Switzerland). GB2 protein sometimes runs as two bands on SDS–
PAGE, depending on the acrylamide concentration of the gel, the
voltage applied across the gel and the electrophoresis time.
Drug treatments of HEK293T cells and cultured hippocampal
neurons were performed 48 h after transfection or at DIV14,
respectively. HEK293T cells were incubated with 8-Br-cAMP for
30 min. Cultured hippocampal neurons were incubated with
H89 for 2 h. Lysates were probed with the primary antibodies
Fig. 3. Binding of KCTD12 to the G-protein bg subunits is modulated by receptor
activation but not by PKA activation. (A) Scheme of the BRET Rluc-Gb1 donor and
Venus-KCTD12 acceptor pair. (B) BRET donor saturation curves from CHO-K1 cells
stably expressing GB1 and GB2 and transiently expressing ﬁxed amounts of Rluc-
Gb1 and Gg2 together with increasing amounts of Venus-KCTD12. Following
receptor activation with baclofen (100 mM, 5 min pre-incubation; grey traces) the
BRET curves were shifted towards higher BRETmax values. Activation of PKA with 8-
Br-cAMP (1 mM, 30 min pre-incubation; open circles) had no effect on the BRET
curves. BRET is expressed as milli BRET units (mBU) determined as net BRET  1000.
Data points are means  SD of technical quadruplicates of a representative
experiment, n = 3.
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Germany) or rabbit anti-GB2-pS892 [13] (1:750) and peroxi-
dase-coupled secondary antibodies donkey anti-guinea pig
(A7289, 1:10,000, Sigma–Aldrich, MO, US) and donkey anti-rabbit
(NA9340, 1:10,000, GE Healthcare, Buckinghamshire, UK). b-III-
Tubulin (T8660, 1:10,000, Sigma–Aldrich, MO, US; peroxidase-
coupled secondary antibody sheep anti-mouse, NA931, 1:10,000,
GE Healthcare, Buckinghamshire, UK) was used to control for
loading and to normalize GB2 and phosphorylated GB2 protein
levels in neurons.
2.7. BRET measurements
BRET measurements were performed as described [19,21].
CHO-K1 cells stably expressing GB1 and GB2 subunits and
HEK293T cells were transiently transfected with plasmids encod-
ing Rluc and YFP fusion proteins and distributed into 96-well
microplates (Greiner Bio-One, Kremsmu¨nster, Austria; coated with
poly-L-ornithine hydrobromide; P3655, Sigma–Aldrich, MO, US) at
a density of 50,000 and 100,000 cells/well, respectively. Twenty-
four hours after transfection, cells were starved for 4 h in DMEM w/
o FCS. After washing, coelenterazine h (5 mM, NanoLight Technol-
ogies, AZ, US) was added with or without 8-Br-cAMP for 30 min.
Luminescence and ﬂuorescence signals were detected sequentially
using an Inﬁnite1 F500 Microplate Reader (Tecan, Ma¨nnedorf,
Switzerland). Baclofen was added 5 min prior measurement. Each
data point represents a technical quadruplicate.
2.8. Data analysis
All data are presented as mean  SD. Statistical signiﬁcance was
assessed using unpaired Student’s t test, one-way ANOVA followed by
Dunnett’s multiple comparison test or two-way ANOVA followed by
Sidak’s multiple comparison test, using Prism 5.04 software
(GraphPad, CA, US). BRET data were analyzed and ﬁtted using a
‘‘one-site speciﬁc binding’’ equation (GraphPad, CA, US).
3. Results
3.1. S892 phosphorylation slows KCTD12-induced K+ current
desensitization
To investigate the effects of S892 phosphorylation on KCTD12-
induced desensitization we performed whole-cell patch-clamp
recordings from CHO-K1 cells expressing KCTD12, GIRK channels
(GIRK1/2) and GB1b together with GB2-WT or the GB2 mutants
S892A (phospho-deﬁcient), S892E (phospho-mimetic) and Y902A
(deﬁcient in KCTD12-binding). Applications of the GABAB receptor
agonist baclofen for 60 s elicited K+ currents with much moreTable 1
Parameters from BRET saturation curves with Rluc-KCTD12 and GB1a-YFP. BRET
donor saturation assays were performed in HEK293T cells transfected with ﬁxed
amounts of GB2-WT or GB2-S892A, Rluc-KCTD12 (donor) and increasing amounts
of GB1a-YFP (acceptor) with and without activation of PKA by pre-incubation with
8-Br-cAMP for 30 min. The BRETmax is the maximal BRET signal obtained for a given
donor/acceptor pair and the BRET50 corresponds to the amount of acceptor needed
to obtain 50% of the BRETmax. Data are presented as the mean  SD of the indicated
number of independent experiments and were derived from data as presented in Fig. 2.
GB2 constructs BRETmax SD BRET50 SD n
GB2-WT 119.0 9.2 0.0037 0.0014 7
GB2-WT, 8-Br-cAMP 132.1* 12.4 0.0042 0.0013 7
GB2-S892A 112.8 3.6 0.0034 0.0008 4
GB2-S892A, 8-Br-cAMP 111.8 4.7 0.0033 0.0004 4
* p < 0.05; compared to GB2-WT; t test.pronounced desensitization in the presence (91.0  3.4%; n = 14;
Fig. 1B) than in the absence of KCTD12 (26.0  7.5%; n = 10; Fig. 1C), as
reported earlier [18]. Approximation of the time-course of the KCTD12-
induced desensitization by a double exponential function yielded time
constants of 1.6  0.4 s (t1; relative amplitude 47.5  15.3%) and
12.9  2.1 s (t2; Fig. 1B) [18,19]. Activation of PKA by pre-incubation of
cells with 8-Br-cAMP for 30 min signiﬁcantly slowed both componentsTable 2
Parameters from BRET saturation curves with Rluc-Gb1 and Venus-KCTD12. BRET
donor saturation assays were performed in CHO-K1 cells stably expressing GABAB
receptors and transiently expressing ﬁxed amounts of Rluc-Gb1 (donor) and Gg2 and
increasing amounts of Venus-KCTD12 (acceptor). To activate GABAB receptors, cells
were pre-incubated with baclofen for 5 min. To activate PKA, cells were pre-
incubated with 8-Br-cAMP for 30 min. The BRETmax is the maximal BRET signal
obtained for a given donor/acceptor pair and the BRET50 corresponds to the amount
of acceptor needed to obtain 50% of the BRETmax. Data are presented as the
mean  SD of the indicated number of independent experiments and were derived
from data as presented in Fig. 3.
GABAB receptor activation BRETmax SD BRET50 SD n
Control, no baclofen 97.9 11.4 0.0490 0.0321 3
8-Br-cAMP, no baclofen 94.3 7.1 0.0517 0.0338 3
Control, baclofen 131.1* 21.9 0.0372 0.0125 3
8-Br-cAMP, baclofen 130.0* 21.9 0.0459 0.0264 3
* p < 0.05; compared to control, no baclofen; compared to 8-Br-cAMP, no
baclofen; t test.
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t2 = 20.8  2.2 s; p < 0.01 and p < 0.001; t test; mean time constant t
shown in Fig. 1G). In contrast, 8-Br-cAMP did not signiﬁcantly inﬂuence
GABAB-activated K
+ currents in the absence of KCTD12 showing that
PKA selectively modulates KCTD12-induced fast desensitization
(Fig. 1C and G). Inhibition of PKA using H89 accelerated desensitization,
suggestive of tonic PKA activity in CHO-K1 cells (t1 = 1.1  0.3 s,
relative amplitude 47.8  19.5%; t2 = 7.2  1.2 s, p < 0.05 and
p < 0.01; t test). 8-Br-cAMP did not inﬂuence desensitization when
expressing GB2-S892A or GB2-S892E instead of GB2-WT (Fig. 1D, E and
G) thus implicating S892 in PKA modulation. Fast desensitization was
not inﬂuenced by PKA when expressing GB2-Y902A (Fig. 1F, G). Of note,Fig. 4. PKA activation slows fast desensitization of baclofen-activated K+ currents in cu
baclofen-activated K+ currents recorded at 50 mV from WT hippocampal neurons. PKA a
grey trace) or H89 (2 mM; dark grey trace). Controls represent recordings from untreate
from double-exponential ﬁts to the decay phase of K+ currents during baclofen applicatio
baclofen-induced K+ current desensitization for the indicated treatments. Data are m
compared to Ctl. Ctl, control; FSK, forskolin; cAMP, 8-Br-cAMP. (C) Representative baclofen
with 8-Br-cAMP (grey trace) or untreated KCTD12/ neurons (control, black trace) as in (A)
baclofen-induced K+ current desensitization for the indicated treatments. Data are meansfast desensitization was already signiﬁcantly slowed (increased t) with
GB2-Y902A compared to GB2-WT in the absence of 8-Br-cAMP
(Fig. 1G). This conﬁrms that assembly of receptors with KCTD12 is
required for PKA regulation of fast desensitization.
Inhibition of PKA accelerates fast desensitization, suggestive of
basal S892 phosphorylation. We therefore investigated whether
repetitive activation of GABAB receptors, which reduces PKA-
dependent phosphorylation of S892 [13], accelerates the KCTD12-
induced desensitization. We recorded K+ currents in response to
repeated baclofen application for 60 s in 5-min intervals. In
experiments with GB2-WT, but not with GB2-S892A, GB2-S892E or
GB2-Y902A, desensitization of the 3rd K+ current response wasltured hippocampal neurons of WT but not of KCTD12/ mice. (A) Representative
ctivity was modulated by pre-incubation for 30 min with 8-Br-cAMP (1 mM; bright
d neurons (black trace). The desensitization time constants t1 and t2 were derived
n (enlarged on the right). (B) Bar graph summarizing the time constants t1 and t2 of
eans  SD, n = 7–35. **, p < 0.01; ***, p < 0.001; Dunnett’s multiple comparison test,
-activated K+ current responses from hippocampal KCTD12/ neurons pre-incubated
. Traces were ﬁtted as in (A). (D) Bar graph summarizing the time constants t1 and t2 of
  SD, n = 5-17, Dunnett’s multiple comparison test, compared to Ctl.
Fig. 5. Basal phosphorylation of S892 is decreased by inhibiting PKA in hippocampal
neurons of WT mice. Western blot of cultured neurons in the presence and absence
of H89 (10 mM, 2 h pre-incubation; left). Inhibition of PKA does not affect the
amount of GB2 protein but decreases the amount of S892 phosphorylation (GB2-
pS892). b-III-Tubulin was used as a loading control. Bar graph summarizing the
amount of phosphorylated S892 (GB2-pS892 in %; right). The total amount of GB2
and GB2-pS892 were normalized to b-III-tubulin on the same blot. Data are
means  SD, n = 6. *, p < 0.05; t test.
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(Fig. 1H, I). In summary, the results show that KCTD12-induced
desensitization of GABAB-activated K
+ currents is regulated by
receptor activity and PKA phosphorylation of S892. Repeated
activation of GABAB receptors results in a sharpening of the receptor
response due to a receptor activity-dependent reduction in S892
phosphorylation.
3.2. S892 phosphorylation rearranges the receptor/KCTD12 complex
It is conceivable that dissociation of KCTD12 from the receptor
underlies the slowing of desensitization in response to PKA
phosphorylation of S892. To test this hypothesis, we used a BRET
assay monitoring the interaction of KCTD12 with GABAB receptors
in living cells [21]. Binding of the donor fusion protein Rluc-
KCTD12 to GB2 allows for speciﬁc BRET to the acceptor fusion
protein GB1a-YFP (Fig. 2A). Expression of increasing amounts of
GB1a-YFP with a ﬁxed amount of Rluc-KCTD12 and GB2-WT
resulted in hyperbolic BRET donor saturation curves, consistent
with a speciﬁc interaction between KCTD12 and GABAB receptors
(Fig. 2B, left). As a control, very low non-speciﬁc linear BRET was
observed between Rluc-KCTD12 and GB1a-YFP in experiments
with GB2-Y902A. When GB2-expressing cells were pre-incubated
with 8-Br-cAMP for 30 min, we still observed a speciﬁc BRET
donor saturation curve. This demonstrates that KCTD12 does not
dissociate from the receptor upon receptor phosphorylation.
However, compared to BRET experiments with untreated cells, the
donor saturation curves in response to PKA activation were
shifted towards higher maximal BRET (BRETmax) values (Fig. 2B,
left, and Table 1). Given that similar amounts of BRET acceptor
were required to reach 50% of the BRETmax signal (BRET50), the
increase in BRETmax most likely reﬂects a conformational
rearrangement in the GABAB receptor/KCTD12 complex and not
a change in the relative afﬁnity of the proteins for one another or
increased levels of GABAB receptors at the plasma membrane.
Western blot analysis demonstrated that 8-Br-cAMP treatment
signiﬁcantly increased phosphorylation of S892 without altering
total GB2 expression levels (Fig. 2C). We next acquired BRET donor
saturation curves for Rluc-KCTD12 and GB1a-YFP in cells
expressing GB2-S892A. As expected, we obtained hyperbolic
BRET donor saturation curves demonstrating a speciﬁc interaction
between KCTD12 and GABAB receptors assembled with GB2-
S892A (Fig. 2B, right). However, 8-Br-cAMP did not alter the
BRETmax and BRET50 values showing that PKA rearranges the
receptor/KCTD12 complex through phosphorylation of S892
(Fig. 2B, right, and Table 1).
The ﬁnding that KCTD12 remains associated with
GABAB receptors when activating PKA was further conﬁrmed in
co-immunoprecipitation experiments showing that similar
amounts of GB2 are associated with KCTD12 in the presence
and absence of 8-Br-cAMP (8-Br-cAMP: 102.8  15.9%, p > 0.05
normalized to without 8-Br-cAMP; t test; n = 5; Fig. 2D). Co-
immunoprecipitation experiments with receptors assembled with
GB2-S892A or GB2-S892E conﬁrmed that phosphorylation of S892 in
GB2 is neither required nor prohibitive for binding of KCTD12
(Fig. 2E).
3.3. PKA does not impair dynamic binding of KCTD12 to the G-
proteins
Since PKA induces a conformational rearrangement in the
receptor/KCTD12 complex, we next investigated whether PKA also
inﬂuences the interaction of KCTD12 with the G-protein [19]. This
can be monitored by BRET between Rluc-Gb1 and Venus-KCTD12
in transfected CHO-K1 cells stably expressing GB1 and GB2
subunits (Fig. 3A). In agreement with KCTD12 dynamicallyinteracting with the G-protein [19], the BRET donor saturation
curves were shifted towards higher BRETmax values following
activation of GABAB receptors with baclofen (Fig. 3B and Table 2).
This agrees with an activity-dependent conformational rearrange-
ment of KCTD12 at the G-protein reported earlier [19]. However, 8-
Br-cAMP did not alter the BRET donor saturation curve between
Rluc-Gb1 and Venus-KCTD12 irrespective of whether GABAB
receptors were activated with baclofen or not (Fig. 3B and
Table 2). These data therefore demonstrate that activation of
PKA does not alter the interaction between KCTD12 and the G-
protein in a measurable way.
3.4. S892 phosphorylation slows KCTD12-induced K+ current
desensitization in cultured hippocampal neurons
We next investigated whether PKA modulates the desensitiza-
tion of GABAB-activated K
+ currents in cultured hippocampal
neurons, which are known to express KCTD12 [18,19,23]. With WT
neurons, K+ currents elicited by 60-s long applications of baclofen
showed a steady-state desensitization of 53.3  9.3% (n = 41,
Fig. 4A). The time course of desensitization was approximated by a
double exponential function with time constants of 1.5  0.3 s (t1)
and 24.4  6.4 s (t2) (Fig. 4B), values that are similar as in earlier
experiments [18,19]. Activation of PKA with 8-Br-cAMP or forskolin
signiﬁcantly increased the fast component t1 of the desensitization,
while inhibition of PKA with H89 or PKI had the opposite effect
(Fig. 4B). Neither activation nor inhibition of PKA had a signiﬁcant
effect on the slow component t2 of the desensitization (Fig. 4B). The
relative contribution of the fast and slow components (t1 and t2,
respectively) to the desensitization did not change with any of the
treatments (t1 of control: 46.5  10.0%; cAMP: 36.3  15.4%; FSK:
40.3  17.8%; H89: 55.7  12.2%; PKI: 47.7  7.7%; p > 0.05; Dun-
nett’s multiple comparison test). These results reveal that PKA
activity speciﬁcally inﬂuences the fast component of baclofen-
induced K+ current desensitization in WT neurons.
In cultured hippocampal neurons of KCTD12/mice [19] t1 but
not t2 was signiﬁcantly increased compared to WT mice (t1 of WT:
1.5  0.3 s; KCTD12/: 2.4  0.9 s; p < 0.001; t2 of WT: 24.4  6.4 s;
KCTD12/: 26.0  8.1 s; p > 0.05; t test; compare Fig. 4B and D).
Neither activation nor inhibition of PKA had a signiﬁcant effect on the
desensitization of baclofen-induced K+ currents in KCTD12/
neurons (Fig. 4D). These data support that the PKA-modulated fast
component of K+ current desensitization in neurons depends on
KCTD12.
Fig. 6. Lack of S892 phosphorylation in S892A knock-in mice accelerates fast desensitization of GABAB-activated K
+ currents. (A) WT and mutated GB2 alleles. The S892 to
alanine mutation (tcc ! gcc) and a silent diagnostic NheI restriction site (gctagc) were introduced into exon 19 using homologous recombination in Balb/c embryonic stem
(ES) cells. Mutated nucleotides are shown in italic. A neomycin marker (neo) ﬂanked by loxP sites (arrowheads) was used for selection of ES cells. Correctly targeted ES cells
(S892A + neo allele) were injected into C57BL/6 blastocysts. A founder mouse was crossed with a Balb/c mouse expressing Cre-recombinase to excise the neomycin cassette,
leaving one loxP site behind (S892A allele). The hybridization probe used in the Southern blot in (B) is indicated. A, alanine; N, NheI restriction sites; S, serine. (B) Southern blot
of NheI cut genomic DNA from correctly targeted ES cells. The probe labels a 15.3 kb fragment for the WT allele and a 4.3 kb fragment for the S892A + neo allele. (C) Western
blot analysis of brain extracts showing that S892A mice express normal levels of GB2, GB1a and GB1b proteins. S892 was phosphorylated in brain extracts of WT but not
S892A mice as shown with an antibody speciﬁc for phosphorylated S892 (GB2-pS892). Brain extracts of GB2-deﬁcient mice (GB2/) [38] conﬁrm the speciﬁcity of the GB2
and GB2-pS892 antibodies. b-III-Tubulin was used as a loading control. (D) Representative GABAB-activated K
+ currents recorded at 50 mV in response to baclofen
application (100 mM) from cultured hippocampal neurons of S892A mice. PKA was activated by pre-incubation for 30 min with 8-Br-cAMP (1 mM; grey trace). Controls
represent recordings from untreated neurons (black trace). The desensitization time constants t1 and t2 were derived from double-exponential ﬁts to the decay phase of K
+
currents during baclofen application (enlarged on the right). (E) Bar graph summarizing the time constants t1 and t2 of baclofen-induced K
+ current desensitization in WT and
S892A neurons. Data are means  SD, n = 5–7. *, p < 0.05; ***, p < 0.001; Sidak’s multiple comparison test.
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Fig. 7. Binding of KCTD12 to GABAB receptors increases S892 phosphorylation. (A)
Lysates of HEK293T cells expressing GB1a and either GB2-WT or GB2-Y902A in the
presence and absence of KCTD12 (up). S892 phosphorylation (GB2-pS892) is
increased in the presence of KCTD12 for GB2-WT, but not for GB2-Y902A. Blots are
representative of ﬁve independent experiments. Bar graph summarizing the
amount of phosphorylated S892 normalized to GB2 protein on the same blot (GB2-
pS892 in %; bottom). Data are means  SD, n = 5. *, p < 0.05; **, p < 0.01; Sidak’s
multiple comparison test. (B) Western blot of lysates from transfected HEK293T cells
expressing the indicated proteins. Phosphorylation of S892 (GB2-pS892) is observed
with GB2-WT and GB2-Y902A but not with GB2-S892A, showing that the pS892
antibody speciﬁcally detects phosphorylation of S892. Note increased phosphorylation
of S892 in the presence of KCTD12 with WT receptors (GB2-WT) compared to mutant
receptors that cannot bind KCTD12 (GB2-Y902A). Blots are representative of three
independent experiments.
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fast desensitization of K+ currents and prevents regulation by PKA
PKA inhibition with H89 or PKI accelerates fast desensitization
of K+ currents in WT hippocampal neurons. Endogenous PKA
activity must therefore provide a high level of basal S892
phosphorylation. Indeed, Western blot analysis of hippocampal
neurons revealed that GB2 is highly phosphorylated at S892
(Fig. 5), which is reduced by inhibition of PKA with H89. We next
addressed whether phosphorylation of S892 in GB2 is essential for
PKA effects on baclofen-induced K+ current desensitization in
neurons. We generated S892A knock-in mice carrying a S892 to
alanine mutation in the GB2 gene using standard gene targeting
techniques (Fig. 6A and B). S892A mice display no overt behavioral
abnormalities. Western blot analysis revealed similar levels of
GB1a, GB1b and GB2 protein in S892A and WT brain extracts
(Fig. 6C). Recordings of baclofen-induced K+ currents from cultured
hippocampal neurons revealed that the desensitization was
signiﬁcantly faster in S892A compared to WT neurons (Fig. 6D
and E). Activation of PKA with 8-Br-cAMP did not signiﬁcantly
increase t1 of the desensitization in S892A neurons, in contrast to
control WT neurons (Fig. 6E). The t2 of the desensitization was
similar in both genotypes and did not change upon activation of
PKA with 8-Br-cAMP (Fig. 6E). The lack of PKA effect in S892A
neurons indicates that S892 phosphorylation is mandatory for
PKA-mediated attenuation of fast desensitization. In summary, our
results show that basal PKA-mediated phosphorylation of S892
slows KCTD12-induced desensitization in neurons.
3.6. Assembly of KCTD12 with GABAB receptors increases S892
phosphorylation
We additionally investigated whether assembly of GABAB
receptors with KCTD12 inﬂuences S892 phosphorylation. We
found that co-expression of KCTD12 with GABAB receptors in
HEK293T cells increases phosphorylation of S892 in WT but not in
GB2-Y902A receptors (Fig. 7). These data reveal that binding of
KCTD12 and phosphorylation of S892 inﬂuence each other.
4. Discussion
4.1. Slow and fast mechanisms of homologous desensitization of
GABAB receptor responses inﬂuence each other
A slow form of homologous desensitization of GABAB receptor
responses relies on the activity-dependent decrease of S892
phosphorylation in GB2 by PKA [13,14]. Here we show that
phosphorylation of S892 by PKA slows KCTD12-induced desensi-
tization, a faster form of desensitization that is induced at the G-
protein rather than at the receptor. We observed a high basal level
of S892 phosphorylation in hippocampal neurons, consistent with
earlier reports [13,30]. Accordingly, KCTD12-induced current
desensitization is signiﬁcantly attenuated in WT hippocampal
neurons compared to GB2-S892A neurons. This may to some
extent explain the moderate desensitization of GABAB-activated K
+
currents in hippocampal neurons, despite a high level of KCTD12
expression [19]. Conversely, KCTD12 promotes S892 phosphory-
lation, which may explain why KCTD12 stabilizes receptors at the
cell surface and increases the magnitude of GABAB receptor
signaling [21]. These results indicate that the mechanism of fast
and slow desensitization inﬂuence each other.
4.2. Interplay of slow and fast desensitization mechanisms
KCTD12 binds to GB2 in close proximity of the PKA
phosphorylation-site S892. In principle, phosphorylation of S892
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would explain the slowing of fast desensitization. However, BRET
analysis and co-immunoprecipitation experiments show that
neither PKA activity nor the phospho-mimetic mutant GB2-
S892E unbind KCTD12 from the receptor. This agrees with earlier
ﬁndings showing that KCTD12 remains associated with the
receptor during receptor activity [21]. However, BRET analysis
revealed that PKA-mediated S892 phosphorylation induces a
conformational change in the receptor/KCTD12 complex without
measurably altering the interaction between KCTD12 and the G-
protein. This suggests that S892 phosphorylation does not stabilize
a receptor/KCTD12 conformation that prevents binding of KCTD12
to Gbg [19]. Since GB2 and KCTD12 both bind to the G-protein the
conformational rearrangement in the receptor/KCTD12 complex
may reduce the rate of G-protein activation [19,27,31–33]. Because
KCTD12-induced desensitization is activity-dependent [19], a
reduction in the G-protein activation rate would slow fast
desensitization.
Conversely, assembly of GABAB receptors with KCTD12
promotes S892 phosphorylation, which may induce a conforma-
tional rearrangement in the cytoplasmic domain of GB2 that makes
S892 more accessible for phosphorylation by PKA. This agrees with
earlier ﬁndings that show that receptors with KCTD12 are more
stable at the cell surface [21].
Overall, the interplay of fast and slow mechanisms of
homologous desensitization will have several effects on GABAB
receptor-activated K+ current responses. Assembly of receptors
with KCTD12 will increase basal S892 phosphorylation and
stabilize receptors at the cell surface [21]. Increased tonic S892
phosphorylation will attenuate KCTD12-induced fast desensitiza-
tion. Conversely, prolonged exposure to agonists will reduce PKA
activity and S892 phosphorylation. This will accelerate KCTD12-
induced fast desensitization and promote slow desensitization due
to receptor degradation. The interplay of the two mechanisms of
desensitization underlies the sharpening of the K+ current
response observed in heterologous cells during repeated receptor
activation. In addition to this homologous regulation of desensiti-
zation, it is possible that other GPCRs regulating cAMP/PKA
signaling modulate GABAB receptor desensitization in a heterolo-
gous manner. Moreover, GABAB receptor desensitization may be
regulated at S892 during neuronal processes in which PKA activity
is altered, such as NMDA-mediated synaptic plasticity, learning
and memory, seizures or during aging [34–37].
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